Vol. 2 No. 10 (2022)
Reimbursement Recommendations

Pralsetinib (Gavreto)

Published October 18, 2022

Key Messages

  • CADTH recommends that Gavreto be reimbursed by public drug plans for the treatment of adult patients with rearranged during transfection (RET) fusion–positive locally advanced unresectable or metastatic non–small cell lung cancer (NSCLC) if certain conditions are met.
  • Gavreto should only be covered to treat adult patients aged 18 years and older with locally advanced unresectable or metastatic RET fusion–positive NSCLC who have never received cancer treatment or who have received cancer treatment. Patients receiving Gavreto should be in relatively good health (i.e., have a good performance status as determined by a specialist) and not have cancer that has spread to the brain or if it has spread to the brain, is controlled.
  • Gavreto should only be reimbursed if prescribed by a clinician with expertise in the management of NSCLC and if the cost of Gavreto is reduced. Gavreto should not be reimbursed in combination with other cancer treatment.